VANCOUVER, BC - TheNewswire - October 6, 2020 - Izotropic Corporation (“Izotropic” or the “Company”) (CSE:IZO) (CNSX:IZO.CN) (US:IZOZF) (FSE:1R3) is pleased to announce the results of its Annual General Meeting held via teleconference on October 2, 2020.

Company matters submitted to shareholders for approval as set out in the Company's Notice of Meeting and Management Information Circular, both dated September 1, 2020, were approved by the requisite majority of votes cast at the meeting.

By a vote of 45.81% of issued and outstanding shares the requisite majority of shareholders approved:

Election of Directors:
Robert Thast
John Boone
Marshall Severyn
Ali Sodagar
Ralph Proceviat

Appointment of Auditor:
Dale Matheson Carr-Hilton LaBonte LLP

Stock Option Plan:
Shareholders approved amendments to, and the renewal of, the Company's Stock Option Plan.

Long Term Performance Incentive Plan:

Shareholders approved amendments to the Company’s Long Term Performance Incentive Plan.

ON BEHALF OF THE BOARD

Robert Thast

Chief Executive Officer

Phone: 1-833-IZOCORP       
Email: info@izocorp.com

Website: izocorp.com

About Izotropic Corp.

Izotropic Corporation and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp. have been established to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires approximately 500 images, without painful breast compression, providing radiologists with fully 3D viewing of the scanned breast. Mammography scanning requires compression of the breast between 2 imaging plates, resulting in 2D images.  

The Company has the exclusive worldwide license from the University of California, Davis to commercialize the technology developed by principal founder and Company director Dr. John M. Boone and researchers at UC Davis. The license includes all intellectual property, trade secrets, patents and patent-pending applications that are the foundation of the Company’s breast CT imaging platform.

Approximately $20 million in research funding and over 15 years of research and development have been invested in developing this groundbreaking breast CT imaging technology. Research includes a current, ongoing $2.9M U.S. clinical trial at UC Davis Medical Center.

The Company founders believe that this technology will be a disruptive entry to the market, overcoming many of the challenges faced by existing breast imaging modalities.

Forward Looking Statements

This document may contain forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.